Simcha hires CEO, expands research agreement
Plus Integra’s Caruso passes away and updates from Ambrx, Cullinan, Zephyr, South Rampart and more
Engineered cytokine therapeutic company Simcha Therapeutics Holding Co. LLC hired Sanuj Ravindran as CEO and a director, and appointed Jake Bauer as independent director and chair. Ravindran was CEO of PellePharm Inc. and executive chair of Phoenix Tissue Repair Inc. — both companies of BridgeBio Pharma Inc. (NASDAQ:BBIO) where he was CEO-in-residence. Bauer, a venture partner with Arch Venture Partners and SR One Capital Management, was CBO of MyoKardia Inc. Simcha also expanded its research agreement with Yale School of Medicine to support company founder Aaron Ring’s laboratory, and holds the exclusive option to license any therapeutic agents that may result.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) said former Chairman and CEO Richard Caruso passed away last weekend. Caruso founded Integra in 1989; the company became the first to market a tissue regeneration product, the Dermal Regeneration Template, which FDA approved in 1996. Caruso served as Integra’s chairman in 1992-2011 and CEO during 1992-97. He served on the board of Susquehanna University and the Baum School of Art...